$CARM
Carisma Therapeutics Inc.

2016 Q2 Form 10-Q Financial Statement

#000148500316000144 Filed on August 12, 2016

View on sec.gov

Income Statement

Concept 2016 Q2 2015 Q2
Revenue $277.0K $114.0K
YoY Change 142.98% -85.02%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.470M $2.250M
YoY Change 54.22% 9.76%
% of Gross Profit
Research & Development $3.298M $6.269M
YoY Change -47.39% -7.18%
% of Gross Profit
Depreciation & Amortization $40.00K $90.00K
YoY Change -55.56% -18.18%
% of Gross Profit
Operating Expenses $6.769M $8.516M
YoY Change -20.51% -3.29%
Operating Profit -$6.492M -$8.402M
YoY Change -22.73% 4.44%
Interest Expense $0.00 -$330.0K
YoY Change -100.0% 317.72%
% of Operating Profit
Other Income/Expense, Net $1.000K $1.496M
YoY Change -99.93% -2068.42%
Pretax Income -$6.490M -$6.910M
YoY Change -6.08% -14.9%
Income Tax
% Of Pretax Income
Net Earnings -$6.491M -$6.906M
YoY Change -6.01% -14.96%
Net Earnings / Revenue -2343.32% -6057.89%
Basic Earnings Per Share -$0.33
Diluted Earnings Per Share -$0.33 -$362.0K
COMMON SHARES
Basic Shares Outstanding 19.88M shares 19.37M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2016 Q2 2015 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $8.500M $53.50M
YoY Change -84.11% 18.89%
Cash & Equivalents $8.484M $53.49M
Short-Term Investments
Other Short-Term Assets $400.0K $900.0K
YoY Change -55.56% -10.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $8.834M $54.43M
YoY Change -83.77% 18.25%
LONG-TERM ASSETS
Property, Plant & Equipment $314.0K $580.0K
YoY Change -45.86% -14.96%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $0.00 $16.00K
YoY Change -100.0% 6.67%
Total Long-Term Assets $433.0K $690.0K
YoY Change -37.25% -12.77%
TOTAL ASSETS
Total Short-Term Assets $8.834M $54.43M
Total Long-Term Assets $433.0K $690.0K
Total Assets $9.267M $55.12M
YoY Change -83.19% 17.72%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.855M $1.880M
YoY Change -1.33% -27.75%
Accrued Expenses $1.153M $618.0K
YoY Change 86.57% -45.79%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00 $2.500M
YoY Change -100.0% 56.25%
Total Short-Term Liabilities $3.008M $5.472M
YoY Change -45.03% -9.21%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $12.20M
YoY Change -100.0% 480.95%
Other Long-Term Liabilities $73.00K $164.0K
YoY Change -55.49% 64.0%
Total Long-Term Liabilities $73.00K $164.0K
YoY Change -55.49% -92.55%
TOTAL LIABILITIES
Total Short-Term Liabilities $3.008M $5.472M
Total Long-Term Liabilities $73.00K $164.0K
Total Liabilities $3.081M $5.636M
YoY Change -45.33% -31.27%
SHAREHOLDERS EQUITY
Retained Earnings -$139.3M -$105.2M
YoY Change 32.41% 44.21%
Common Stock $20.00K $19.00K
YoY Change 5.26% 18.75%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $6.173M $37.22M
YoY Change
Total Liabilities & Shareholders Equity $9.267M $55.12M
YoY Change -83.19% 17.72%

Cashflow Statement

Concept 2016 Q2 2015 Q2
OPERATING ACTIVITIES
Net Income -$6.491M -$6.906M
YoY Change -6.01% -14.96%
Depreciation, Depletion And Amortization $40.00K $90.00K
YoY Change -55.56% -18.18%
Cash From Operating Activities -$5.010M -$9.030M
YoY Change -44.52% 6.86%
INVESTING ACTIVITIES
Capital Expenditures $0.00 -$260.0K
YoY Change -100.0% 225.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities $0.00 -$260.0K
YoY Change -100.0% 225.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 70.00K 17.23M
YoY Change -99.59% -4302.44%
NET CHANGE
Cash From Operating Activities -5.010M -9.030M
Cash From Investing Activities 0.000 -260.0K
Cash From Financing Activities 70.00K 17.23M
Net Change In Cash -4.940M 7.940M
YoY Change -162.22% -188.81%
FREE CASH FLOW
Cash From Operating Activities -$5.010M -$9.030M
Capital Expenditures $0.00 -$260.0K
Free Cash Flow -$5.010M -$8.770M
YoY Change -42.87% 4.78%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2016
dei Document Period End Date
DocumentPeriodEndDate
2016-06-30
dei Document Type
DocumentType
10-Q
dei Entity Central Index Key
EntityCentralIndexKey
0001485003
CY2016Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
20058298 shares
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Registrant Name
EntityRegistrantName
Eleven Biotherapeutics, Inc.
dei Trading Symbol
TradingSymbol
EBIO
ebio Change In Fair Value Of Preferred Stock Warrants
ChangeInFairValueOfPreferredStockWarrants
102000 USD
CY2016Q2 ebio Collaboration Revenue
CollaborationRevenue
200000 USD
ebio Collaboration Revenue
CollaborationRevenue
400000 USD
CY2016Q2 ebio Fair Value Assets Liabilities Transfer Between Levels
FairValueAssetsLiabilitiesTransferBetweenLevels
0 USD
ebio Fair Value Assets Liabilities Transfer Between Levels
FairValueAssetsLiabilitiesTransferBetweenLevels
0 USD
ebio Issuance Of Warrant For Common Stock
IssuanceOfWarrantForCommonStock
328000 USD
ebio Issuance Of Warrant For Common Stock
IssuanceOfWarrantForCommonStock
0 USD
CY2016Q2 ebio Working Capital Net
WorkingCapitalNet
5800000 USD
CY2015Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1246000 USD
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-915000 USD
CY2016Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
1855000 USD
CY2015Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1794000 USD
CY2016Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1153000 USD
CY2015Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
194000 USD
CY2016Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
77000 USD
CY2015Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
144126000 USD
CY2016Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
145420000 USD
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3269884 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3240757 shares
CY2015Q4 us-gaap Assets
Assets
36825000 USD
CY2016Q2 us-gaap Assets
Assets
9267000 USD
CY2015Q4 us-gaap Assets Current
AssetsCurrent
36311000 USD
CY2016Q2 us-gaap Assets Current
AssetsCurrent
8834000 USD
CY2015Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
36079000 USD
CY2016Q2 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
8484000 USD
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
54059000 USD
CY2015Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
53494000 USD
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
36079000 USD
CY2016Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
8484000 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-565000 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-27595000 USD
CY2015Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2016Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2015Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2016Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2015Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2016Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2015Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
19619124 shares
CY2016Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
20005771 shares
CY2015Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
19619124 shares
CY2016Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
20005771 shares
CY2015Q4 us-gaap Common Stock Value
CommonStockValue
20000 USD
CY2016Q2 us-gaap Common Stock Value
CommonStockValue
20000 USD
CY2015Q4 us-gaap Construction Payable Current
ConstructionPayableCurrent
931000 USD
CY2016Q2 us-gaap Construction Payable Current
ConstructionPayableCurrent
160000 USD
CY2015Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
406000 USD
CY2016Q2 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
0 USD
us-gaap Depreciation And Amortization
DepreciationAndAmortization
192000 USD
us-gaap Depreciation And Amortization
DepreciationAndAmortization
93000 USD
CY2015Q4 us-gaap Derivative Fair Value Of Derivative Liability
DerivativeFairValueOfDerivativeLiability
115000 USD
CY2016Q2 us-gaap Derivative Fair Value Of Derivative Liability
DerivativeFairValueOfDerivativeLiability
13000 USD
CY2015Q4 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
115000 USD
CY2016Q2 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
13000 USD
CY2015Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.36
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.72
CY2016Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.33
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.71
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0 USD
us-gaap Fair Value Assumptions Risk Free Interest Rate
FairValueAssumptionsRiskFreeInterestRate
0.0052
CY2015Q2 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0 USD
CY2016Q2 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0 USD
us-gaap Fair Value Assumptions Expected Volatility Rate
FairValueAssumptionsExpectedVolatilityRate
0.7943
CY2015 us-gaap Fair Value Assumptions Risk Free Interest Rate
FairValueAssumptionsRiskFreeInterestRate
0.0106
CY2015Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
573000 USD
CY2016Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
915000 USD
CY2016Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
3100000 USD
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y10M6D
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-3123000 USD
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-102000 USD
CY2015 us-gaap Fair Value Assumptions Expected Dividend Rate
FairValueAssumptionsExpectedDividendRate
0.0000
us-gaap Fair Value Assumptions Expected Dividend Rate
FairValueAssumptionsExpectedDividendRate
0.0000
CY2015 us-gaap Fair Value Assumptions Expected Term
FairValueAssumptionsExpectedTerm
P1Y11M1D
us-gaap Fair Value Assumptions Expected Term
FairValueAssumptionsExpectedTerm
P1Y5M1D
CY2015 us-gaap Fair Value Assumptions Expected Volatility Rate
FairValueAssumptionsExpectedVolatilityRate
0.7067
CY2015Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2247000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4850000 USD
CY2016Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3471000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5618000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-578000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
609000 USD
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-1209000 USD
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-991000 USD
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-55000 USD
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-406000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
596000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
126000 USD
us-gaap Increase Decrease In Restricted Cash For Operating Activities
IncreaseDecreaseInRestrictedCashForOperatingActivities
0 USD
us-gaap Increase Decrease In Restricted Cash For Operating Activities
IncreaseDecreaseInRestrictedCashForOperatingActivities
25000 USD
CY2015Q2 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-330000 USD
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-565000 USD
CY2016Q2 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
0 USD
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-247000 USD
us-gaap Interest Paid
InterestPaid
374000 USD
us-gaap Interest Paid
InterestPaid
663000 USD
CY2015Q4 us-gaap Interest Payable Current
InterestPayableCurrent
88000 USD
CY2016Q2 us-gaap Interest Payable Current
InterestPayableCurrent
0 USD
CY2015Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
36825000 USD
CY2016Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
9267000 USD
CY2015Q4 us-gaap Liabilities Current
LiabilitiesCurrent
7580000 USD
CY2016Q2 us-gaap Liabilities Current
LiabilitiesCurrent
3008000 USD
CY2015Q4 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
115000 USD
CY2016Q2 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
13000 USD
CY2015Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
9763000 USD
CY2016Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-6492000 USD
CY2016Q2 us-gaap Long Term Notes Payable
LongTermNotesPayable
0 USD
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
17228000 USD
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
-14036000 USD
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-286000 USD
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
0 USD
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-17507000 USD
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-13559000 USD
CY2015Q2 us-gaap Net Income Loss
NetIncomeLoss
-6906000 USD
us-gaap Net Income Loss
NetIncomeLoss
-13430000 USD
CY2016Q2 us-gaap Net Income Loss
NetIncomeLoss
-6491000 USD
us-gaap Net Income Loss
NetIncomeLoss
-14065000 USD
CY2015Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1496000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2569000 USD
CY2016Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1023000 USD
CY2015Q4 us-gaap Notes Payable Current
NotesPayableCurrent
4134000 USD
CY2016Q2 us-gaap Notes Payable Current
NotesPayableCurrent
0 USD
CY2015Q2 us-gaap Operating Expenses
OperatingExpenses
8516000 USD
us-gaap Operating Expenses
OperatingExpenses
16357000 USD
CY2016Q2 us-gaap Operating Expenses
OperatingExpenses
6769000 USD
us-gaap Operating Expenses
OperatingExpenses
13548000 USD
CY2015Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-8402000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-15999000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-13042000 USD
CY2015Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
8000 USD
CY2016Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1000 USD
CY2015Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
13000 USD
CY2016Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
0 USD
CY2015Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
423000 USD
CY2016Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
73000 USD
CY2015Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1826000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
3134000 USD
CY2016Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
139000 USD
us-gaap Paid In Kind Interest
PaidInKindInterest
26000 USD
us-gaap Paid In Kind Interest
PaidInKindInterest
26000 USD
us-gaap Payments For Restructuring
PaymentsForRestructuring
0 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
286000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
0 USD
CY2015Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2016Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2015Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2016Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2015Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2016Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2015Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2016Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2015Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2016Q2 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2015Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
232000 USD
CY2016Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
350000 USD
us-gaap Proceeds From Collaborators
ProceedsFromCollaborators
1750000 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
12172000 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0 USD
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
5000000 USD
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
0 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
56000 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
88000 USD
CY2015Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
407000 USD
CY2016Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
314000 USD
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
0 USD
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
14124000 USD
CY2015Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6269000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
11507000 USD
CY2016Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3298000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7930000 USD
CY2015Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
94000 USD
CY2016Q2 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
119000 USD
CY2016Q2 us-gaap Restructuring And Related Cost Expected Cost1
RestructuringAndRelatedCostExpectedCost1
600000 USD
CY2016Q2 us-gaap Restructuring Charges
RestructuringCharges
600000 USD
CY2015Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-125202000 USD
CY2016Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-139267000 USD
CY2015Q2 us-gaap Revenues
Revenues
114000 USD
us-gaap Revenues
Revenues
358000 USD
CY2016Q2 us-gaap Revenues
Revenues
277000 USD
us-gaap Revenues
Revenues
506000 USD
CY2015Q2 us-gaap Share Based Compensation
ShareBasedCompensation
602000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
1266000 USD
CY2016Q2 us-gaap Share Based Compensation
ShareBasedCompensation
621000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
1207000 USD
CY2016Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
891327 shares
CY2016Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
6.05
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
297711 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
981352 shares
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1803574 shares
CY2016Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2205774 shares
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
6.28
CY2016Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.78
CY2016Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
1923413 shares
CY2016Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
5.20
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.29
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
3.60
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0.39
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
281441 shares
CY2015Q4 us-gaap Stockholders Equity
StockholdersEquity
18944000 USD
CY2016Q2 us-gaap Stockholders Equity
StockholdersEquity
6173000 USD
CY2015Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
19087000 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
18532000 shares
CY2016Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
19874000 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
19756000 shares
us-gaap Write Off Of Deferred Debt Issuance Cost
WriteOffOfDeferredDebtIssuanceCost
0 USD
us-gaap Write Off Of Deferred Debt Issuance Cost
WriteOffOfDeferredDebtIssuanceCost
221000 USD

Files In Submission

Name View Source Status
0001485003-16-000144-index-headers.html Edgar Link pending
0001485003-16-000144-index.html Edgar Link pending
0001485003-16-000144.txt Edgar Link pending
0001485003-16-000144-xbrl.zip Edgar Link pending
ebio-063016x101.htm Edgar Link pending
ebio-063016x10q.htm Edgar Link pending
ebio-063016x311.htm Edgar Link pending
ebio-063016x312.htm Edgar Link pending
ebio-063016x321.htm Edgar Link pending
ebio-20160630.xml Edgar Link completed
ebio-20160630.xsd Edgar Link pending
ebio-20160630_cal.xml Edgar Link unprocessable
ebio-20160630_def.xml Edgar Link unprocessable
ebio-20160630_lab.xml Edgar Link unprocessable
ebio-20160630_pre.xml Edgar Link unprocessable
ebiologoa06.jpg Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending